Tools
Tools
Campbell, Suzanne, Osei-Atweneboana, Mike, Stothard, Russell 
ORCID: https://orcid.org/0000-0002-9370-3420, Koukounari, Artemis, Cunningham, Lucas, Armoo, Samuel, Biritwum, Nana-Kwadwo, Gyapong, Margaret, MacPherson, Eleanor ORCID: https://orcid.org/0000-0002-7142-1158, Theobald, Sally ORCID: https://orcid.org/0000-0002-9053-211X, Woode, Maame, Khan, Jahangir ORCID: https://orcid.org/0000-0002-6151-764X, Niessen, Louis ORCID: https://orcid.org/0000-0002-8639-5191 and Adams, Emily ORCID: https://orcid.org/0000-0002-0816-2835
(2018)
'The COUNTDOWN Study Protocol for Expansion of Mass Drug Administration Strategies against Schistosomiasis and Soil-Transmitted Helminthiasis in Ghana'. Tropical Medicine and Infectious Disease, Vol 3, Issue 1, p. 10.
|
Text
tropicalmed)mass drug administration.pdf - Published Version Available under License Creative Commons Attribution. Download (869kB) | Preview |
Abstract
Background: Current international policy for schistosomiasis and soil-transmitted helminthiasis (STH) control emphasises mass administration of deworming drugs in school-based programmes. However, this approach is insufficient to control the transmission of these diseases, and their burden in non-school cohorts is recognised, albeit under-researched. This research will investigate the feasibility and acceptability of expanding access to praziquantel (PZQ) against schistosomiasis, and albendazole (ALB) against STH, to communities in selected transmission settings in Ghana. (2) Methods: A three-site longitudinal study will be implemented to investigate the effectiveness of expanding treatment strategies for PZQ and ALB to community members. In the context of community mass drug administration (to preschool children, school non-attending children, and adults, including pregnant women), the intervention will be assessed in a random sample of community members, at baseline with follow-up at 6, 12, and 18 months. In each community, 658 participants will be enrolled, and 314 followed up at each time point. The primary outcome measure is the prevalence of infection of Schistosoma haematobium and/or S. mansoni at study endpoint, as assessed by longitudinal surveys. Secondary outcomes are to quantify the infection of schistosomiasis and STH infections in non-treated cohorts, reductions in prevalence of STH, and intensity of schistosomiasis and STH, and treatment coverage. Nested within this study will be qualitative, cost-benefit, and cost-effectiveness evaluations that will explore accessibility, feasibility, and economic impact of expanded treatment from different complementary perspectives. (3) Discussion: Using a multidisciplinary approach, this study will generate evidence for improved availability, acceptability, affordability, and accessibility to deworming drugs against schistosomiasis and STH to individuals and communities in Ghana. This is likely to have considerable research, programmatic, and political value to contribute evidence for national programme policy development within Ghana, and, more broadly, World Health Organization policy development.
| Item Type: | Article |
|---|---|
| Subjects: | QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 253 Anthelmintics WA Public Health > Health Problems of Special Population Groups > WA 395 Health in developing countries WC Communicable Diseases > Tropical and Parasitic Diseases > WC 810 Schistosomiasis |
| Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology Clinical Sciences & International Health > Clinical Sciences Department Clinical Sciences & International Health > International Public Health Department |
| Digital Object Identifer (DOI): | https://doi.org/10.3390/tropicalmed3010010 |
| SWORD Depositor: | JISC Pubrouter |
| Depositing User: | Stacy Murtagh |
| Date Deposited: | 01 Feb 2018 09:38 |
| Last Modified: | 02 Dec 2019 12:53 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/8159 |
Statistics
Actions (login required)
 |
Edit Item |